Wastewater monitoring is becoming increasingly critical for monitoring community health to detect outbreaks of COVID-19 and the spread of other infectious diseases
Collaboration combines QIAcuity digital PCR instruments and sample preparation from QIAGEN with highly sensitive wastewater SARS-COV-2 assay from GT Molecular
Joint solution launched in August sets new standards, especially how quickly results can be achieved in under two and a half hours
Workflow complies with CDC guidelines for new wastewater monitoring systems in the United States, also designed for use in Canada and other countries around the world
HILDEN, Germany & GERMANTOWN, Md. & FORT COLLINS, Colorado, August 10, 2021– (BUSINESS WIRE) – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and GT Molecular, a leader in providing customizable and highly sensitive digital PCR and qPCR assays based in the United States, have started offering a Complete workflow for wastewater solution designed to enable monitoring of COVID-19 outbreaks by US and Canadian laboratories, with future options to offer the solution in other countries.
The workflow leverages QIAGEN’s sample preparation expertise and its innovative QIAcuity digital PCR system, which hosts GT Molecular’s SARS-CoV-2 digital wastewater monitoring test. The test was developed to comply with CDC guidelines for the United States National Wastewater Surveillance System (NWSS). The full workflow has been available since early August, when the test was launched.
In response to the pandemic and authorities’ demand for health data on large segments of the population, the solution is setting new standards. It allows the quantification of SARS-CoV-2 in wastewater in less than two and a half hours, compared to up to 6 hours with other dPCR systems. In addition, the integration of QIAGEN’s AllPrep PowerViral DNA / RNA Kit, which leverages QIAGEN’s patented Inhibitor Removal TechnologyÂ®, with robust multiplex dPCR detection on the QIAcuity Digital PCR System, enables highly accurate RNA analysis. viral from wastewater samples that are generally highly variable.
âThere are different methods and workflows for testing SARS-CoV-2 in wastewater and developing and optimizing them can be difficult and time consuming,â said Thomas Schweins, Senior Vice President of the Business Area. of QIAGEN Life Sciences. âQIAGEN and GT Molecular offer a complete solution for the detection of SARS-CoV-2 and its variants that significantly reduces the initial investment time for our customers working in the public health field. “
âGT Molecular is delighted to partner with QIAGEN to provide this cutting-edge solution that will play a key role in the fight against the pandemic,â said Christopher McKee, CEO of GT Molecular, a Colorado-based company with extensive experience in water testing and develop SARS-CoV-2 tests. âOur ultra-sensitive test and the QIAcuity platform have combined to form a fast, easy-to-use and highly accurate system for tracking and managing the spread of COVID-19. “
The wastewater-based epidemiology (WBE) of SARS-CoV-2 allows public authorities to collect data from broad segments of the population, including those not included in public health statistics because they do not have access to health care or do not seek tests. Wastewater monitoring has the potential to reveal viral infection and mutational dynamics earlier than diagnostic tests. This near real-time information will allow public health officials to take faster action to deal with SARS-CoV-2 outbreaks.
Interest in wastewater testing increased during the pandemic. Authorities in the United States and other countries have already started looking at other targets beyond SARS-CoV-2. Additionally, researchers in various countries have been able to detect influenza, norovirus and other pathogens in wastewater, suggesting that the usefulness of WBE will remain even after COVID-19 is controlled.
More information on QIAGEN’s solutions for the detection of SARS-CoV-2 in wastewater can be found here.
About GT Molecular
GT Molecular is a leader in providing highly customizable, ultra-sensitive digital PCR and qPCR assays and services for the detection of cancer and harmful pathogens, including SARS-CoV-2 and its variants. GTM’s technology is an easy-to-use solution for rapid deployment and provides reliable and consistent measurements while detecting as few as 1 to 3 target nucleic acid molecules. The tests have been used in testing labs across the United States to accurately detect and monitor pathogen levels, providing high-quality data for epidemiological studies and actionable policy decisions. http://www.gtmolecular.com
QIAGEN NV, a Netherlands-based holding company, is the world’s leading provider of Sample to Insight solutions that enable customers to gain valuable molecular information from samples containing the building blocks of life. Our sampling technologies isolate and process DNA, RNA and proteins from blood, tissues and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to yield relevant and actionable information. Automation solutions connect them in transparent and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers worldwide in the fields of molecular diagnostics (human health) and life sciences (universities, pharmaceutical R&D and industrial applications, mainly forensic). As of June 30, 2021, QIAGEN employed approximately 5,900 people at more than 35 locations around the world. Further information is available at http://www.qiagen.com
Certain statements contained in this press release may be considered as forward-looking statements within the meaning of Section 27A of the US Securities Act of 1933, as amended, and Section 21E of the US Securities Exchange Act of 1934, as ‘fine. To the extent that any of the statements contained herein regarding QIAGEN’s products, including products used in the COVID-19 pandemic response, launch and development schedule, marketing approvals and / or regulatory, financial and operating outlook, growth and expansion, collaborative markets, strategy or operating results, including, without limitation, its expected adjusted net sales and adjusted earnings results diluted, are forward-looking, these statements are based on current expectations and assumptions which involve a number of uncertainties and risks. These uncertainties and risks include, but are not limited to, the risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and reliance on logistics), variability in results operations and allocations between customer categories; commercial development of markets for our products to academic, pharmaceutical, applied testing and molecular diagnostics customers; changing relationships with customers, suppliers and strategic partners; competetion; rapid or unexpected technological changes; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, level and timing of customer financing, budgets and other factors); our ability to obtain regulatory approval for our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; QIAGEN’s ability to identify and develop new products and to differentiate and protect our products from competitive products; market acceptance of new QIAGEN products and integration of acquired technologies and businesses; government actions, global or regional economic developments, weather or transport delays, natural disasters, political or public health crises, including the extent and duration of the COVID-19 pandemic and its impact on demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that the expected benefits associated with recent or ongoing acquisitions will not materialize as expected; and the other factors discussed under the heading âRisk Factorsâ in Section 3 of our most recent Annual Report on Form 20-F. For more information, please refer to the discussions in the reports that QIAGEN has filed with, or provided to, the United States Securities and Exchange Commission.
Source: QIAGEN SA
See the source version on businesswire.com: https://www.businesswire.com/news/home/20210810005962/en/
John Gilardi, +49 2103 29 11711
Phoebe Loh, +49 2103 29 11457
email: [email protected]
Thomas Theuringer, +49 2103 29 11826
Robert Reitze, +49 2103 29 11676
email: [email protected]